Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06574763 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer

StatusUnknown
PhasePhase 2
Started2024-09-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 28, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Not Yet Recruiting → Unknown
The goal of this phase II single arm prospective clinical study is to evaluate the efficacy and toxicity of RC48 plus carboplatin neoadjuvant therapy in HER2 expressed epithelial ovarian cancer patients. The main questions it aims to answer are: * The improvement of complete resection rate and pathological complete rate of this regimen. * The delayed effect of treatment regimens on patient's recurrence.
Trial Details
NCT Number NCT06574763
Lead Sponsor Sun Yat-sen University
Conditions Ovarian Cancer
Enrollment 47 participants
Start Date 2024-09-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-28